141 related articles for article (PubMed ID: 37236167)
21. Now you see me, now you don't: Isolated central nervous system recurrence of CD19-negative diffuse large B-cell lymphoma following CD19-directed CAR T-cell treatment.
Gokozan HN; Ouseph MM; Carniello JVS; Besien KV; Patel SS
Cytopathology; 2022 Nov; 33(6):757-759. PubMed ID: 35713946
[TBL] [Abstract][Full Text] [Related]
22. CAR T in patients with large B-cell lymphoma not fit for autologous transplant.
Kuhnl A; Kirkwood AA; Roddie C; Menne T; Tholouli E; Bloor A; Besley C; Chaganti S; Osborne W; Norman J; Gibb A; Sharplin K; Cuadrado M; Correia de Farias M; Cheok K; Neill L; Latif AL; González Arias C; Uttenthal B; Jones C; Johnson R; McMillan A; Sanderson R; Townsend W
Br J Haematol; 2023 Jul; 202(1):65-73. PubMed ID: 37082780
[TBL] [Abstract][Full Text] [Related]
23.
Derlin T; Schultze-Florey C; Werner RA; Möhn N; Skripuletz T; David S; Beutel G; Eder M; Ross TL; Bengel FM; Ganser A; Koenecke C
Ann Nucl Med; 2021 Jan; 35(1):132-138. PubMed ID: 33174144
[TBL] [Abstract][Full Text] [Related]
24. Modern management of relapsed and refractory aggressive B-cell lymphoma: A perspective on the current treatment landscape and patient selection for CAR T-cell therapy.
Bachanova V; Perales MA; Abramson JS
Blood Rev; 2020 Mar; 40():100640. PubMed ID: 31780119
[TBL] [Abstract][Full Text] [Related]
25. Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?
Shah NN; Ahn KW; Litovich C; He Y; Sauter C; Fenske TS; Hamadani M
Blood; 2021 Mar; 137(10):1416-1423. PubMed ID: 33120429
[TBL] [Abstract][Full Text] [Related]
26. CD19-directed CAR T-cell therapy in B-cell NHL.
Kersten MJ; Spanjaart AM; Thieblemont C
Curr Opin Oncol; 2020 Sep; 32(5):408-417. PubMed ID: 32740094
[TBL] [Abstract][Full Text] [Related]
27. Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma.
Wudhikarn K; Palomba ML; Pennisi M; Garcia-Recio M; Flynn JR; Devlin SM; Afuye A; Silverberg ML; Maloy MA; Shah GL; Scordo M; Dahi PB; Sauter CS; Batlevi CL; Santomasso BD; Mead E; Seo SK; Perales MA
Blood Cancer J; 2020 Aug; 10(8):79. PubMed ID: 32759935
[TBL] [Abstract][Full Text] [Related]
28. [Eligibility of patients for CAR T-cell: Expert opinion-based collaborative work by the SFGM-TC].
Beauvais D; Bachy E; Baruchel A; Bay JO; Caillot D; Cartron G; Damaj G; Furst S; Le Gouill S; Morschhauser F; Rabian F; Rubio MT; Thieblemont C; Yakoub-Agha I
Bull Cancer; 2021; 108(7-8):725-729. PubMed ID: 33423776
[TBL] [Abstract][Full Text] [Related]
29. Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma.
Wei J; Zhu X; Mao X; Huang L; Meng F; Zhou J
J Immunother Cancer; 2019 Nov; 7(1):315. PubMed ID: 31753002
[TBL] [Abstract][Full Text] [Related]
30. [How to perform leukapheresis for procurement of the staring material used for commercial CAR T-cell manufacturing: A consensus from experts convened by the SFGM-TC].
Carnoy S; Beaumont JL; Kanouni T; Parquet N; Beauvais D; Hequet O; Kanold J; Ballot C; Mialou V; Reppel L; Damaj G; Yakoub-Agha I; Chabannon C
Bull Cancer; 2021 Mar; 108(3):295-303. PubMed ID: 33610284
[TBL] [Abstract][Full Text] [Related]
31. Progressive multifocal leukoencephalopathy after CAR T therapy.
Sdrimas K; Diaz-Paez M; Camargo JF; Lekakis LJ
Int J Hematol; 2020 Jul; 112(1):118-121. PubMed ID: 32125605
[TBL] [Abstract][Full Text] [Related]
32. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
[TBL] [Abstract][Full Text] [Related]
33. [Current status of diagnosis and treatment in diffuse large B-cell lymphoma].
Shimada K
Rinsho Ketsueki; 2021; 62(8):1077-1084. PubMed ID: 34497194
[TBL] [Abstract][Full Text] [Related]
34. Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma.
Qasrawi A; Arora R; Ramlal R; Munker R; Hildebrandt GC
Am J Hematol; 2020 Apr; 95(4):E89-E91. PubMed ID: 31919891
[No Abstract] [Full Text] [Related]
35. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.
Sesques P; Ferrant E; Safar V; Wallet F; Tordo J; Dhomps A; Karlin L; Brisou G; Vercasson M; Hospital-Gustem C; Schwiertz V; Ranchon F; Rioufol C; Choquet M; Sujobert P; Ghergus D; Bouafia F; Golfier C; Lequeu H; Lazareth A; Novelli S; Devic P; Traverse Glehen A; Viel S; Venet F; Mialou V; Hequet O; Chauchet A; Arkam Y; Nicolas-Virelizier E; Peyrade F; Cavalieri D; Ader F; Ghesquières H; Salles G; Bachy E
Am J Hematol; 2020 Nov; 95(11):1324-1333. PubMed ID: 32744738
[TBL] [Abstract][Full Text] [Related]
36. Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma.
Hashmi H; Mirza AS; Darwin A; Logothetis C; Garcia F; Kommalapati A; Mhaskar RS; Bachmeier C; Chavez JC; Shah B; Pinilla-Ibarz J; Khimani F; Lazaryan A; Liu H; Davila ML; Locke FL; Nishihori T; Jain MD
Blood Adv; 2020 Sep; 4(17):4086-4090. PubMed ID: 32877523
[TBL] [Abstract][Full Text] [Related]
37. CXCR5
Tang J; Zha J; Guo X; Shi P; Xu B
Int Immunopharmacol; 2017 Sep; 50():146-151. PubMed ID: 28662433
[TBL] [Abstract][Full Text] [Related]
38. A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?
Zhang J; Li J; Ma Q; Yang H; Signorovitch J; Wu E
Adv Ther; 2020 Jul; 37(7):3040-3058. PubMed ID: 32524498
[TBL] [Abstract][Full Text] [Related]
39. [Medium-term follow-up of patients treated with chimeric antigen receptor T cells (CAR T cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Alsuliman T; Drieu La Rochelle L; Campidelli A; Duléry R; Fayard A; Mamez AC; Mear JB; Schneider PO; Trevet A; Vicente C; Yakoub-Agha I
Bull Cancer; 2021 Dec; 108(12S):S65-S71. PubMed ID: 33678408
[TBL] [Abstract][Full Text] [Related]
40. Preliminary outcomes reported from three randomized controlled trials of CD19 CAR-T cell therapies in large B cell lymphoma.
Jain MD
Mol Ther; 2022 Jan; 30(1):14-16. PubMed ID: 34921770
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
